WHAT IS GENE THERAPY

Your Heart Sickle Cell Foundation, Inc.

YHSCF

 

 

Sickle cell disease gene therapy is a groundbreaking treatment designed to correct the genetic mutation that causes sickle cell disease. The two FDA-approved gene therapies—Casgevy and Lyfgenia—offer potential cures by modifying a patient’s blood stem cells to produce healthy red blood cells.

• Casgevy uses CRISPR gene-editing technology to increase fetal hemoglobin levels, preventing red blood cells from sickling.

• Lyfgenia introduces a functional hemoglobin-producing gene using a viral vector, restoring normal red blood cell function.

• Both therapies require stem cell collection, genetic modification, chemotherapy, and transplantation, making them complex but highly effective treatments. Early results show significant reductions in pain crises and improved blood health, offering hope to patients with severe sickle cell disease.

• If you’d like to explore more details, you can check out this FDA announcement or this expert discussion.

​

The new gene therapies for sickle cell disease—Casgevy and Lyfgenia—are considered groundbreaking treatments that offer potential cures for the condition.

• Casgevy uses CRISPR gene-editing technology to modify a patient’s blood stem cells, increasing the production of fetal hemoglobin, which prevents red blood cells from sickling.

• Lyfgenia delivers a healthy hemoglobin-producing gene using a viral vector, aiming to restore normal red blood cell function.

• Both therapies are designed to be one-time treatments, but long-term studies are still needed to confirm their durability. Early results show significant reductions in pain crises and improved blood health, offering hope to patients who previously had limited options.

• If you’d like to dive deeper, you can check out the FDA’s announcement or Yale Medicine’s insights. 

​

Casgevy and Lyfgenia are among the most expensive treatments available for any health condition.

• Casgevy had an introductory list price of $2.2 million per patient.

• Lyfgenia debuted with a cost of $3.1 million per patient.

• These prices may vary depending on insurance coverage, financial assistance programs, and negotiated rates.

• If you're interested in learning more about payment options, you can check out this article for details on insurance and financial support.

 

Gene therapies are among the most expensive medical treatments available, with costs often reaching millions of dollars. Here are some examples:

• Libmeldy (for metachromatic leukodystrophy): $4.25 million per treatment, making it one of the most expensive therapies. 

• Hemgenix (for hemophilia B): $3.5 million per dose.

• Zynteglo (for beta-thalassemia): $2.8 million per treatment.

• Skysona (for cerebral adrenoleukodystrophy): $3 million per dose.

• Vyjuvek (for dystrophic epidermolysis bullosa): The lifetime cost could be as high as $15–$22 million per patient.

• These therapies offer life-changing benefits, but their high costs raise concerns about accessibility and insurance coverage. Some insurers offer outcome-based agreements, where payments are spread over time and rebates are issued if the therapy does not provide expected benefits.

• If you're interested in more details, you can check out this article on gene therapy pricing and this discussion on insurance coverage.

​​

Gene therapy for sickle cell disease is expensive due to several factors:

• Complex Treatment Process: Patients undergo stem cell collection, genetic modification, chemotherapy, and transplantation, requiring specialized medical teams and facilities.

• High Research & Development Costs: Developing gene therapies involves years of research, clinical trials, and regulatory approvals, which cost hundreds of millions of dollars.

• Limited Patient Population: Sickle cell disease primarily affects Black and African American communities, and the relatively small number of eligible patients means companies must price treatments high to recover costs.

• Hospitalization & Recovery: Patients often require extended hospital stays, immune system recovery, and follow-up care, adding to the overall cost.

• Insurance & Accessibility Challenges: Many insurers and Medicaid programs are struggling to develop new payment models to make these therapies more accessible.

• If you’d like to explore more details, you can check out this article on payment models and this discussion on cost factors. ​​​​​

​

Smile for Supporting Sickle Cell Adult Survivors and Sickle Cell Disease Awareness.

​​

Burgundy Ribbon Sponsor -                  $5,000 

Table of Triumph Sponsor -                   $2,500

Quench Your Thirst Sponsor -               $2,000

Hot Springs Breeze Sponsor -               $1,500

Nutritionist Empowerment Sponsor -   $1,250

Sunny Sails Sponsor -                             $1,000

 

Who Can Be a Sponsor and Donor, You Can.

Make your contributions today.

All Donations are acceptable.​